Non-invasive early detection of cancer four years before conventional diagnosis using a blood test.

Chen X, et al. Nat Commun. 2020;11(1):3475.

Cell-free DNA analysis in current cancer clinical trials: a review.

Cisneros-Villanueva M, et al. Br J Cancer. 2022;126(3):391-400.

Projected reductions in absolute cancer–related deaths from diagnosing cancers before metastasis, 2006–2015.

Clarke CA, et al. Cancer Epidemiol Biomarkers Prev. 2020;29(5):895-902.

Circulating tumor DNA (ctDNA) as a pan-cancer screening test: is it finally on the horizon?

Duffy MJ, et al. Clin Chem Lab Med. 2021;59(8):1353-1361.

Modeled reductions in late-stage cancer with a multi-cancer early detection test.

Hubbell E, et al. Cancer Epidemiol Biomarkers Prev. 2021;30(3):460-468.

Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set.

Klein EA, et al. Ann Oncol. 2021;32(9):1167-1177.

Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA.

Liu MC, et al. Ann Oncol. 2020;31(6):745-759.

The PATHFINDER Study: assessment of the implementation of an investigational multi-cancer early detection test into clinical practice.

Nadauld LD, et al. Cancers (Basel). 2021;13(14):3501.

Updates on liquid biopsy: current trends and future perspectives for clinical application in solid tumors. 

Pinzani P, et al. Clin Chem Lab Med. 2021;59(7):1181-1200.

Sensitivity, specificity, and predictive values: foundations, pliabilities, and pitfalls in research and practice.

Trevethan R. Front Public Health. 2017;5.

Liquid biopsies come of age: towards implementation of circulating tumour DNA.

Wan JCM, et al. Nat Rev Cancer. 2017;17(4):223-238.